ArticleArthritis care & research2026
Evaluating the Longitudinal Association of Rheumatoid Arthritis Disease Activity With Phenotypic Frailty: Evidence for Secondary Frailty?
Article in Arthritis care & research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Evaluating a Pragmatic Strength Alternative for Frailty Measurement and Assessing Its Predictive Capacity Against Established Frailty Instruments in Rheumatoid Arthritis.Arthritis care & research · 2026Article
- Frailty in rheumatoid arthritis and the general population: a cross-sectional analysis of the Groningen Frailty Indicator and Fried criteria.Rheumatology (Oxford, England) · 2026Article
- Frailty Transition and Risk of New-Onset Arthritis Among Adults Aged 45 Years and Older: A Longitudinal Analysis of CHARLS.Healthcare (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
objectiveThe cross-sectional association between rheumatoid arthritis (RA) disease activity and frailty has been described; however, the longitudinal relationship is less well understood. We evaluated the association between disease activity and frailty over time.
methodsWe used a longitudinal RA cohort established at the Department of Veterans Affairs Puget Sound Health Care System. RA disease activity (Disease Activity Score in 28 joints using the C-reactive protein level [DAS28-CRP]) and frailty (measured by the Fried Frailty Phenotype [FFP]) were evaluated at baseline and at one year. Frailty was categorized as robust, prefrail, or frail. Ordinal logistic regressions assessed the cross-sectional associations of DAS28-CRP and frailty at baseline and at one year. Paired t-tests and multivariable mixed ordinal logistic regressions assessed the longitudinal associations of DAS28-CRP and frailty. Models were adjusted for age, sex, disease duration, prednisone use, conventional synthetic disease-modifying antirheumatic drug (DMARD) use, and biologic DMARD use.
resultsA total of 132 patients with RA aged 64.2 ± 11.3 years were included; 73% were male, 69% were White, 11% were Black, and 12% reported multiple races. The mean ± SD baseline DAS28-CRP was 3.9 ± 1.3, and frailty was categorized as robust in 35 (27%) patients, prefrail in 77 (58%) patients, and frail in 20 (15%) patients. DAS28-CRP (per 1-unit increase) was associated with a higher FFP category at baseline (adjusted odds ratio [aOR] 1.98, P < 0.0001). Disease activity increased in those whose frailty score worsened at one year (mean ± SD change score 0.61 ± 0.96, P = 0.0121). An increased DAS28-CRP was independently associated with a higher frailty category over one year (aOR 3.31, P < 0.0001; n = 65).
conclusionDisease activity is independently associated with phenotypic frailty. Increased disease activity over time is associated with worsening frailty status. Future studies are needed to explore this longitudinal relationship and to determine if controlling disease activity can mitigate frailty.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.